Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 5, 2004, Pages 1209-1211

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

1 adrenoceptor antagonists; Benign prostatic hyperplasia; Clinical trial; Doxazosin; Finasteride

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; DOXAZOSIN; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN;

ARTICLE; ASTHENIA; BLADDER EMPTYING; CLINICAL STUDY; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIBIDO DISORDER; NOCTURIA; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RECURRENT INFECTION; RISK REDUCTION; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY HESITANCY; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

CLINICAL TRIALS; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXPERT TESTIMONY; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; SULFONAMIDES;

EID: 2542604729     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.5.1209     Document Type: Article

References (8)

1. MCCONNELL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.
2. GORMLEY GI, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. (1992) 327:1185-1191.
3. BOYLE MJ, FOWLER FJ Jr, O'LEARY MP et al.: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology (1996) 48:398-405.
4. DOGGRELL SA: Present and future pharmacotherapy for benign prostatic hyperplasia. Drugs of the Future (2002) 27:973-986.
5. LEPOR H, WILLIFORD WO, BARRY MJ et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. (1996) 335:533-539.
6. LEPOR H, WILLIFORD WO, BARRY et al.: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J. Urol. (1998) 160:1358-1367.
7. KIRKBY RS, ROEHRBORN C, BOYLE P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European and Combination Therapy (PREDICT) trial. Urology (2003) 61:119-126.
8. KENNY BA, MILLER AM, WILLIAMSON IJ et al.: Evaluation of the pharmacological selectivity of α-adrenoceptors at prostatic α-adrenoceptors: Binding functional and in vivo studies. Br. J. Pharmacol. (1996) 118:871-878.